Sai Life Sciences Limited reported a 12% year-over-year revenue growth for the first quarter of FY27, reaching ₹553 crore. The CRO business saw a significant increase of 26%, while the CDMO segment grew by 6%. The company highlighted strong momentum, advancements in its integrated CRDMO model, and strategic investments in new modalities like peptides and XDCs, positioning it for sustained growth.
Q1 FY27 Financial Highlights
Sai Life Sciences Limited announced its financial results for the first quarter ended August 07, 2026, reporting a total revenue of ₹553 crore. This represents a 12% increase compared to ₹496 crore in the same quarter last year. The CDMO business contributed approximately 60% of the total revenues, with the CRO business making up the remaining 40%. On a year-over-year basis, CRO revenues increased by approximately 26%, while CDMO revenues grew by around 6%.
The company maintained a healthy balance sheet, emphasizing financial flexibility for future investments. Sai Life Sciences continues to balance investments in growth with disciplined capital allocation and returns.
Business Segment Performance and Strategy
Discovery Business
The discovery chemistry services segment continued to scale, with a pilot collaboration successfully converted into a long-term, high-volume discovery chemistry partnership. Significant investments in biology and DMPK, alongside expanded discovery chemistry capabilities, are now translating into integrated service delivery for a majority of customers, primarily biotech clients. The company is also seeing traction with large pharmaceutical clients for integrated models.
CMC Business
The CMC business demonstrated continued strength with 33 active commercial molecules and 14 molecules in late phase. Dedicated FTE development contracts are identified as a key differentiator, augmenting the pipeline of late-phase and commercial molecules. Over the past 15 months, six late-phase molecules have been added, with five originating from large pharma clients engaged in FTE agreements. One significant collaboration has evolved into an end-to-end engagement covering the entire product lifecycle.
Strategic Initiatives and Future Outlook
Sai Life Sciences is enhancing its capabilities across various modalities, including peptides and XDCs (eXtra-cellular Drug Conjugates). The company is investing in a peptide development lab and plans a peptide manufacturing facility expected to be operational by 2028. An XDC Center of Excellence is also being established to support synthesis of payloads, linkers, and conjugation. Formulation is identified as a new area of entry, aiming to provide integrated offerings for custom APIs and drug products.
The company is committed to building depth in scientific capability and talent, with structured management development programs and an intensified Sai Academy. This strategy aims to position Sai Life Sciences as a preferred partner for large pharmaceutical companies seeking scientifically led partners with end-to-end program ownership.
Sai Life Sciences reiterated its confidence in sustaining longer-term revenue growth guidance of 15% to 20% and an EBITDA range of 28% to 30%.
Source: BSE
